News
Eli Lilly reported second quarter earnings Thursday, a day after competitor Novo Nordisk missed earnings estimates by Wall ...
Pharmaceutical Technology on MSN12h
Mounjaro and Zepbound fuel strong Q2 growth for Eli LillyEli Lilly reported $15.56bn in revenue, driven by its weight loss and diabetes drugs, intensifying pressure on rival Novo ...
Eli Lilly ( LLY 0.64%) has been one of the best-performing pharmaceutical leaders in the past five years. Thanks to strong ...
Eli Lilly and Company (NYSE:LLY) is one of the most profitable growth stocks to buy according to billionaires. On August 1, ...
Eli Lilly's weight-loss drug is no longer on the Food and Drug Administration's drug shortage list. Compounding pharmacies say this will limit patient access.
Shares of Eli Lilly and Co. rose during trading Wednesday following the news. Tirzepatide was previously approved to treat Type 2 diabetes and was sold under the brand name Mounjaro.
Eli Lilly says its working to expand its manufacturing capacity, to ramp up in anticipation of approval. As with any medication, tirzepatide has some side effects.
The list price of tirzepatide for weight loss is $1,059.87 per month for six different dose sizes, which is about 20% lower than that of Wegovy, Eli Lilly said in a press release.
From the price of forthcoming weight loss pill orforglipron, to Most Favored Nation drug pricing and the market battle with ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback